News

InvisiShield Technologies Ltd., a pre-clinical-stage biotechnology company focused on developing intranasal preventives for major disease-causing respiratory viruses, announced a…
Read More...

Processa Pharmaceuticals, Inc. announced that the Company has dosed the first patient in its NGC-Capecitabine (combination of PCS6422 and capecitabine) 300 mg dose group. The Processa…
Read More...

Alphamab Oncology announced that the first patient has been dosed with 2.1mg/kg in a Phase I clinical study (JSKN003-102) of JSKN003, an Anti-HER2 bispecific ADC. ADC drugs have the…
Read More...

Telix Pharmaceuticals Limited announces that the United States Food and Drug Administration (FDA) has approved a supplementary New Drug Application (sNDA) for Illuccix (kit for the…
Read More...

Ipsen announced that the U.S. Food and Drug Administration (FDA) Prescription Drug User Fee Act (PDUFA) goal date, for the resubmitted New Drug Application (NDA) for investigational…
Read More...

Evotec SE announced progress within the Company’s strategic partnership with Bristol Myers Squibb relating to building a molecular glue-based pipeline. Performance-based and…
Read More...

Novartis announced the U.S. Food and Drug Administration (FDA) granted approval for Tafinlar (dabrafenib) + Mekinist (trametinib) for the treatment of pediatric patients 1 year of age…
Read More...

RELIEF THERAPEUTICS Holding SA, a biopharmaceutical company committed to advancing treatment paradigms and delivering improvements in efficacy, safety and convenience to benefit the…
Read More...

Prelude Therapeutics Incorporated (Prelude) announced a clinical trial collaboration with BeiGene, for future evaluation of its investigational CDK9 inhibitor, PRT2527, in combination…
Read More...

Immunoprecise Antibodies Ltd. announced that Talem Therapeutics LLC, an independently operating subsidiary of IPA, and Libera Bio S.L., have signed a collaboration agreement to jointly…
Read More...

UCB, a global biopharmaceutical company, and Aitia, a leader in the application of Causal AI and “Digital Twins” to discover and develop new drugs, announced an early drug discovery…
Read More...

GSK plc announced that the China National Medical Products Administration has accepted for review a new drug application for Nucala (mepolizumab) as an add-on maintenance treatment for…
Read More...

AcelRx Pharmaceuticals, Inc. announced the divestment of its FDA-approved drug, DSUVIA to Alora Pharmaceuticals (Alora).  The agreement allows AcelRx to participate in the long-term…
Read More...

Pfizer Inc. and BioNTech SE announced that the U.S. Food and Drug Administration (FDA) granted emergency use authorization (EUA) to provide a single booster dose of the companies’…
Read More...

Cingulate Inc., a biopharmaceutical company utilizing its proprietary Precision Timed Release (PTR) drug delivery platform technology to build and advance a pipeline of next-generation…
Read More...

Sanofi and Provention Bio, Inc., a U.S.-based, publicly traded biopharmaceutical company focused on intercepting and preventing immune-mediated diseases including type 1 diabetes (T1D),…
Read More...

Pfizer Inc. and Seagen Inc. announced that they have entered into a definitive merger agreement under which Pfizer will acquire Seagen, a global biotechnology company that discovers,…
Read More...

Cytovance Biologics, Inc. (Cytovance Biologics), a biopharmaceutical contract development and manufacturing organization (CDMO), and Phenotypeca Limited (Phenotypeca), a research and…
Read More...

Cancer Research UK and UCB announced a clinical development collaboration to advance two of UCB’s investigational oncology antibody candidates through clinical trials. The…
Read More...

Sandoz signed a Memorandum of Understanding (MOU) to build a new biologics production plant in Lendava, Slovenia. The Sandoz investment is expected to be at least USD 400 million,…
Read More...